Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 AUROBINDO PHARMA   MYLAN
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-24
MYLAN
Dec-18
AUROBINDO PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1,1774,023-   
Low Rs5172,214-   
Sales per share (Unadj.) Rs495.01,851.2-  
Earnings per share (Unadj.) Rs54.150.3-  
Cash flow per share (Unadj.) Rs80.1396.9-  
Dividends per share (Unadj.) Rs4.500-  
Avg Dividend yield %0.50-  
Book value per share (Unadj.) Rs509.32,002.7-  
Shares outstanding (eoy) m585.94514.50-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x1.71.7 101.6%   
Avg P/E ratio x15.762.0 25.2%  
P/CF ratio (eoy) x10.67.9 134.6%  
Price / Book Value ratio x1.71.6 106.8%  
Dividend payout %8.30-   
Avg Mkt Cap Rs m496,2901,604,616 30.9%   
No. of employees `000NA35.0 0.0%   
Total wages/salary Rs m39,2290-   
Avg. sales/employee Rs Th027,213.0-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0738.9-  
INCOME DATA
Net Sales Rs m290,019952,456 30.4%  
Other income Rs m5,5740-   
Total revenues Rs m295,593952,456 31.0%   
Gross profit Rs m56,340246,460 22.9%  
Depreciation Rs m15,217178,337 8.5%   
Interest Rs m2,89745,810 6.3%   
Profit before tax Rs m43,80022,313 196.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m12,110-3,550 -341.1%   
Profit after tax Rs m31,69025,863 122.5%  
Gross profit margin %19.425.9 75.1%  
Effective tax rate %27.6-15.9 -173.8%   
Net profit margin %10.92.7 402.4%  
BALANCE SHEET DATA
Current assets Rs m237,719531,851 44.7%   
Current liabilities Rs m121,991387,778 31.5%   
Net working cap to sales %39.915.1 263.8%  
Current ratio x1.91.4 142.1%  
Inventory Days Days1784 20.2%  
Debtors Days Days6193 65.0%  
Net fixed assets Rs m196,532184,761 106.4%   
Share capital Rs m586507 115.5%   
"Free" reserves Rs m297,8420-   
Net worth Rs m298,4281,030,383 29.0%   
Long term debt Rs m21,3491,112,114 1.9%   
Total assets Rs m438,5892,763,889 15.9%  
Interest coverage x16.11.5 1,083.9%   
Debt to equity ratio x0.11.1 6.6%  
Sales to assets ratio x0.70.3 191.9%   
Return on assets %7.92.6 304.1%  
Return on equity %10.62.5 423.1%  
Return on capital %14.63.2 459.3%  
Exports to sales %32.90-   
Imports to sales %11.50-   
Net fx Rs m60,1520-   
CASH FLOW
From Operations Rs m24,345197,920 12.3%  
From Investments Rs m-42,560-102,303 41.6%  
From Financial Activity Rs m8,004-92,203 -8.7%  
Net Cashflow Rs m-10,0681,640 -614.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 84.52 Rs / USD

Compare AUROBINDO PHARMA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare AUROBINDO PHARMA With: AVON ORGANIC  VALIANT LABORATORIES LTD.  SYNCOM FORMULATIONS  ADVANCED ENZYME TECHNOLOGIES  COLINZ LABOR  



Today's Market

Sensex Today Rallies 1,961 points | Nifty Above 23,900 | 4 Reasons Why Indian Share Market is Rising Sensex Today Rallies 1,961 points | Nifty Above 23,900 | 4 Reasons Why Indian Share Market is Rising(Closing)

After opening the day higher, Indian benchmark indices remained positive as the session progressed and ended the day on firm footing.